These trials completed more than 12 months ago and should have reported results. Some have, some have not.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Reported results 2005-005665-11 EVALUATION OF THE EFFICACY AND SAFETY OF SILODOSIN vs. TAMSULOSIN AND PLACEBO IN THE TREATMENT OF THE SIGNS AND SYMPTOMS OF BENIGN PROSTATIC HYPERPLASIA. MULTICENTRE, RANDOMISED, DOUBLE-BLIND, CONTRO... 2008-01-04 due-trials
Not reported 2008-004557-15 10 days clinical pilot study to investigate the wound healing efficacy of Mirfulan® ointment (containing zinc oxide and cod liver) in an intra-individual comparison with a placebo, zinc oxide and cod ... 2008-11-28 due-trials
Reported results 2009-015988-13 AN INTERNATIONAL MULTICENTRE, RANDOMIZED, PARALLEL GROUP, DOUBLE-BLIND TRIAL TO EVALUATE DIFFERENT DOSE COMBINATIONS OF LERCANIDIPINE AND ENALAPRIL IN COMPARISON WITH EACH COMPONENT ADMINISTERED AL... 2011-03-02 due-trials
Completed, but no date, and reported results 2010-019524-31 Safety of an ACE-I/CCB fixed combination (Lercanidipine/Enalapril) in elderly hypertensive patients not adequately controlled by CCB monotherapy bad-data
Reported results 2011-000045-20 EFFECTIVENESS AND SAFETY OF SILODOSIN IN THE TREATMENT OF LUTS IN PATIENTS WITH BENIGN PROSTATIC HYPERPLASIA: A EUROPEAN PHASE IV CLINICAL STUDY 2013-07-17 due-trials
Ongoing 2011-004609-26 Evaluation of the efficacy and safety of two methadone titration methods for the treatment of cancer-related pain with inadequate pain relief or intolerable side effects when treated with level 3 opio... not-yet-due
Reported results 2012-002451-41 EFFICACY AND SAFETY OF A SINGLE TRUS-GUIDED INTRAPROSTATIC INJECTION OF NX-1207 IN PATIENTS WITH LOWER URINARY TRACT SYMPTOMS ASSOCIATED WITH BENIGN PROSTATIC HYPERPLASIA: A PHASE III EUROPEAN CLINIC... 2015-01-29 due-trials
Listed as ongoing, but also has a completion date 2013-000267-84 An open label, multicenter pasireotide roll over protocol for patients who have completed a previous Novartis sponsored pasireotide study and are judged by the investigator to benefit from continued p... 2023-10-30 bad-data
Completed, but no date, and reported results 2015-002277-38 Urodynamic evaluation by pressure flow urodynamic study of the new α1A-adrenoceptor antagonist silodosin 8 mg qd in patients with benign prostatic obstruction. Explorative, single-arm, phase IV clinic... bad-data
Exempt, with results 2017-000905-19 EFFECTS OF TWO DIFFERENT DOSES OF REC 0/0438 ADMINISTERED BY INTRA-VESICAL INSTILLATION IN PATIENTS WITH NEUROGENIC DETRUSOR OVERACTIVITY DUE TO SPINAL CORD INJURY: A REPEATED DOSES, DOUBLE-BLIND, PL... 2019-03-27 not-yet-due
Listed as ongoing, but also has a completion date 2017-002840-34 An open-label, multi-center, roll-over study to assess long-term safety in patients with endogenous Cushing’s syndrome who have completed a prior Novartis-sponsored osilodrostat (LCI699) study and are... 2023-11-16 bad-data
Ongoing 2018-001522-25 A phase II, multicenter, open-label, non-comparative study to evaluate the pharmacokinetics, pharmacodynamics, and tolerability of osilodrostat in children and adolescent patients with Cushing’s disea... not-yet-due
Listed as ongoing, but also has a completion date 2018-002984-24 Open-label, Single-arm, Multicenter Study to Assess the Safety of Cystadrops® in Pediatric Cystinosis Patients from 6 Months to Less Than 2 Years Old [SCOB2 Study] 2022-12-23 bad-data
Other 2019-002475-34 Efficacy, Safety and Pharmacokinetics of 3 Doses of REC 0/0559 Eye Drops for the Treatment of Stage 2 (Moderate) and 3 (Severe) Neurotrophic Keratitis in Adult Patients not-yet-due

Related organisations

Over time organisations can merge, or split.

We think Recordati S.p.A. is now also responsible for the trials of: